Suchergebnisse - "Hydroxyurea therapeutic use"

Polycythaemia vera

Autoren: Claire N. Harrison Tiziano Barbui Prithviraj Bose et al.

Quelle: Harrison, C N, Barbui, T, Bose, P, Kiladjian, J-J, Mascarenhas, J, McMullin, M F, Mesa, R & Vannucchi, A M 2025, 'Polycythaemia vera', Nature reviews. Disease primers, vol. 11, 26. https://doi.org/10.1038/s41572-025-00608-3

Schlagwörter: Janus Kinase 2/genetics, Hydroxyurea/therapeutic use, Mutation/genetics, Aspirin, Janus Kinase 2, Pyrazoles/therapeutic use, Pyrimidines, Polycythemia Vera/genetics, Risk Factors, Aspirin/therapeutic use, Mutation, Nitriles, Humans, Hydroxyurea, Pyrazoles, name=SDG 3 - Good Health and Well-being, Polycythemia Vera

Dateibeschreibung: application/pdf

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/40246933
https://pure.qub.ac.uk/en/publications/b29d7492-259c-4d19-96e8-93f57da5c958

Azathioprine/hydroxyurea preconditioning prior to nonmyeloablative matched sibling donor hematopoietic stem cell transplantation in adults with sickle cell disease: A prospective observational cohort study: A prospective observational cohort study

Autoren: Elisabeth Dovern Mesire Aydin Mette D. Hazenberg et al.

Quelle: American Journal of Hematology. 99:1523-1531

Schlagwörter: Adult, Male, Graft Rejection, Hematopoietic Stem Cell Transplantation/methods, Transplantation Conditioning, Hydroxyurea/therapeutic use, Alemtuzumab/therapeutic use, Graft vs Host Disease, Anemia, Sickle Cell, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Sickle Cell/therapy, Azathioprine, Humans, Hydroxyurea, Prospective Studies, Alemtuzumab, Transplantation Conditioning/methods, Graft Rejection/prevention & control, Transplantation Chimera, Siblings, Hematopoietic Stem Cell Transplantation, Anemia, Middle Aged, 3. Good health, Female, Graft vs Host Disease/prevention & control, Azathioprine/therapeutic use

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/38733340

Interferon alpha‐2 treatment reduces circulating neutrophil extracellular trap levels in myeloproliferative neoplasms

Autoren: Laura Massarenti Trine Alma Knudsen Christian Enevold et al.

Quelle: Massarenti, L, Knudsen, T A, Enevold, C, Skov, V, Kjær, L, Larsen, M K, Larsen, T S, Hansen, D L, Hasselbalch, H C & Nielsen, C H 2023, ' Interferon alpha-2 treatment reduces circulating neutrophil extracellular trap levels in myeloproliferative neoplasms ', British Journal of Haematology, vol. 202, no. 2, pp. 318-327 . https://doi.org/10.1111/bjh.18845

Schlagwörter: Janus Kinase 2/genetics, Myeloproliferative Disorders, Myeloproliferative Disorders/drug therapy, Hydroxyurea/therapeutic use, neutrophil extracellular traps (NETs), Interferon alpha-2, Janus Kinase 2, Extracellular Traps, 3. Good health, interferon alpha (IFN-α), Neoplasms, Mutation, Humans, Hydroxyurea, JAK2V617F, myeloproliferative neoplasm (MPN), thrombosis

Dateibeschreibung: application/pdf

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/37211985
https://curis.ku.dk/ws/files/409639674/Interferon_alpha_2_treatment_reduces_circulating_neutrophil_extracellular_trap_levels_in_1_.pdf

Genomic profiling of a randomized trial of interferon-α vs hydroxyurea in MPN reveals mutation-specific responses

Autoren: Trine Alma Knudsen Vibe Skov Kristen Stevenson et al.

Quelle: Blood Adv
Knudsen, T A, Skov, V, Stevenson, K E, Werner, L, Duke, W, Laurore, C, Gibson, C J, Nag, A, Thorner, A R, Wollison, B, Hansen, D L, Ellervik, C, El Fassi, D, de Stricker, K, Ocias, L F, Brabrand, M, Bjerrum, O W, Overgaard, U M, Frederiksen, M, Kristensen, T K, Kruse, T A, Thomassen, M, Mourits-Andersen, T, Severinsen, M T, Stentoft, J, Starklint, J, Neuberg, D S, Kjaer, L, Larsen, T S, Hasselbalch, H C, Lindsley, R C & Mullally, A 2022, 'Genomic Profiling of a Randomized Trial of Interferon-α versus Hydroxyurea in MPN Reveals Mutation-Specific Responses', Blood advances, vol. 6, no. 7, pp. 2107–2119. https://doi.org/10.1182/bloodadvances.2021004856
Knudsen, T A, Skov, V, Stevenson, K, Werner, L, Duke, W, Laurore, C, Gibson, C J, Nag, A, Thorner, A R, Wollison, B, Hansen, D L, Ellervik, C, Fassi, D E, de Stricker, K, Ocias, L F, Brabrand, M, Bjerrum, O W, Overgaard, U M, Frederiksen, M, Kristensen, T K, Kruse, T A, Thomassen, M, Mourits-Andersen, T, Severinsen, M T, Stentoft, J, Starklint, J, Neuberg, D S, Kjaer, L, Larsen, T S, Hasselbalch, H C, Lindsley, R C & Mullally, A 2022, 'Genomic profiling of a randomized trial of interferon-α vs hydroxyurea in MPN reveals mutation-specific responses', Blood Advances, vol. 6, no. 7, pp. 2107-2119. https://doi.org/10.1182/bloodadvances.2021004856
Knudsen, T A, Skov, V, Stevenson, K, Werner, L, Duke, W, Laurore, C, Gibson, C J, Nag, A, Thorner, A R, Wollison, B, Hansen, D L, Ellervik, C, Fassi, D E, de Stricker, K, Ocias, L F, Brabrand, M, Bjerrum, O W, Overgaard, U M, Frederiksen, M, Kristensen, T K, Kruse, T A, Thomassen, M, Mourits-Andersen, T, Severinsen, M T, Stentoft, J, Starklint, J, Neuberg, D S, Kjaer, L, Larsen, T S, Hasselbalch, H C, Lindsley, R C & Mullally, A 2022, ' Genomic profiling of a randomized trial of interferon-a vs hydroxyurea in MPN reveals mutation-specific responses ', Blood advances, vol. 6, no. 7, pp. 2107-2119 . https://doi.org/10.1182/bloodadvances.2021004856
Knudsen, T A, Skov, V, Stevenson, K E, Werner, L, Duke, W, Laurore, C, Gibson, C J, Nag, A, Thorner, A R, Wollison, B, Hansen, D L, Ellervik, C, El Fassi, D, de Stricker, K, Ocias, L F, Brabrand, M, Bjerrum, O W, Overgaard, U, Frederiksen, M, Kristensen, T, Kruse, T, Thomassen, M, Mourits-Andersen, T, Severinsen, M T, Stentoft, J, Starklint, J, Neuberg, D, Kjaer, L, Larsen, T S, Hasselbalch, H C, Lindsley, R C & Mullally, A 2022, ' Genomic profiling of a randomized trial of interferon-α vs hydroxyurea in MPN reveals mutation-specific responses ', Blood Advances, vol. 6, no. 7, pp. 2107-2119 . https://doi.org/10.1182/bloodadvances.2021004856

Schlagwörter: 0301 basic medicine, 0303 health sciences, Myeloid Neoplasia, Myeloproliferative Disorders, Hydroxyurea/therapeutic use, Myeloproliferative Disorders/drug therapy, Interferon-alpha/therapeutic use, Interferon-alpha, Genomics, 3. Good health, 03 medical and health sciences, Mutation, Humans, Hydroxyurea

Dateibeschreibung: application/pdf

Zugangs-URL: https://ashpublications.org/bloodadvances/article-pdf/doi/10.1182/bloodadvances.2021004856/1822059/bloodadvances.2021004856.pdf
https://pubmed.ncbi.nlm.nih.gov/34507355
https://vbn.aau.dk/en/publications/genomic-profiling-of-a-randomized-trial-of-interferon-%CE%B1-versus-hy
https://pubmed.ncbi.nlm.nih.gov/34507355/
https://ashpublications.org/bloodadvances/article-pdf/doi/10.1182/bloodadvances.2021004856/1822059/bloodadvances.2021004856.pdf
https://www.sciencedirect.com/science/article/pii/S2473952921005310
https://pure-portal.regsj.dk/en/publications/genomic-profiling-of-a-randomized-trial-of-interferon-%CE%B1-versus-hy
https://pure.au.dk/ws/files/331564034/advancesadv2021004856.pdf
https://curis.ku.dk/ws/files/305397922/advancesadv2021004856.pdf
https://portal.findresearcher.sdu.dk/da/publications/32f4a9e6-9101-4b7d-8581-2f2bd670fd61
https://doi.org/10.1182/bloodadvances.2021004856
https://findresearcher.sdu.dk:8443/ws/files/201081075/Open_Access_Version.pdf

Cytoreductive treatment in real life: a chart review analysis on 1440 patients with polycythemia vera

Autoren: Carl C. Crodel Kathleen Jentsch-Ullrich Marcel Reiser et al.

Quelle: J Cancer Res Clin Oncol

Schlagwörter: 03 medical and health sciences, 0302 clinical medicine, Aspirin, Phlebotomy, Original Article – Clinical Oncology, Humans, Hydroxyurea, Hydroxyurea/therapeutic use [MeSH], Aged [MeSH], Humans [MeSH], Polycythemia Vera/genetics [MeSH], Polycythemia Vera/therapy [MeSH], PV, Cytoreduction Surgical Procedures [MeSH], Phlebotomy [MeSH], Cytoreduction, Polycythemia vera, Myeloproliferative neoplasia, Aspirin/therapeutic use [MeSH], MPN, Cytoreduction Surgical Procedures, Polycythemia Vera, Aged, 3. Good health

Zugangs-URL: https://link.springer.com/content/pdf/10.1007/s00432-021-03855-5.pdf
https://pubmed.ncbi.nlm.nih.gov/34807311
https://europepmc.org/article/PMC/PMC8607972
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8607972
https://link.springer.com/content/pdf/10.1007/s00432-021-03855-5.pdf
https://pubmed.ncbi.nlm.nih.gov/34807311/
https://link.springer.com/article/10.1007/s00432-021-03855-5
https://repository.publisso.de/resource/frl:6446890

Ruxolitinib-treated polycythemia vera patients and their risk of secondary malignancies

Autoren: Sekhri, Rohit Sadjadian, Parvis Becker, Tatjana et al.

Quelle: Ann Hematol
Ann. Hematol., DOI: 10.1007/s00277-021-04647-0 (2021)

Schlagwörter: Adult, Male, 0301 basic medicine, Lymphoma, Mutation, Missense, 03 medical and health sciences, Nitriles, Humans, Hydroxyurea, Polycythemia Vera, Aged, Proportional Hazards Models, Aged, 80 and over, ddc:610, 0303 health sciences, Incidence, Neoplasms, Second Primary, Janus Kinase 2, Middle Aged, Cytoreductive Therapy, Non-melanoma Skin Carcinomas, Ruxolitinib, Secondary Malignancy, 3. Good health, Pyrimidines, Primary Myelofibrosis, Pyrazoles, Original Article, Female, Hydroxyurea/therapeutic use [MeSH], Aged, 80 and over [MeSH], Pyrazoles/adverse effects [MeSH], Aged [MeSH], Pyrazoles/therapeutic use [MeSH], Neoplasms, Second Primary/chemically induced [MeSH], Risk [MeSH], Mutation, Missense [MeSH], Neoplasms, Second Primary/epidemiology [MeSH], Proportional Hazards Models [MeSH], Male [MeSH], Primary Myelofibrosis/etiology [MeSH], Hydroxyurea/adverse effects [MeSH], Cytoreductive therapy, Pyrimidines [MeSH], Skin Neoplasms/chemically induced [MeSH], Lymphoma/chemically induced [MeSH], Female [MeSH], Follow-Up Studies [MeSH], Janus Kinase 2/genetics [MeSH], Primary Myelofibrosis/chemically induced [MeSH], Adult [MeSH], Humans [MeSH], Polycythemia Vera/drug therapy [MeSH], Polycythemia Vera/genetics [MeSH], Incidence [MeSH], Retrospective Studies [MeSH], Middle Aged [MeSH], Skin Neoplasms/epidemiology [MeSH], Nitriles [MeSH], Polycythemia vera, Non-melanoma skin carcinomas, Secondary malignancy, Lymphoma/epidemiology [MeSH], Follow-Up Studies

Dateibeschreibung: application/pdf

Zugangs-URL: https://link.springer.com/content/pdf/10.1007/s00277-021-04647-0.pdf
https://pubmed.ncbi.nlm.nih.gov/34462786
https://pubmed.ncbi.nlm.nih.gov/34462786/
https://link.springer.com/article/10.1007%2Fs00277-021-04647-0
https://paperity.org/p/271038365/ruxolitinib-treated-polycythemia-vera-patients-and-their-risk-of-secondary-malignancies
https://link.springer.com/content/pdf/10.1007/s00277-021-04647-0.pdf
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510903
https://pub.uni-bielefeld.de/record/2957095
https://doi.org/10.1007/s00277-021-04647-0
https://push-zb.helmholtz-muenchen.de/frontdoor.php?source_opus=62859
https://hss-opus.ub.ruhr-uni-bochum.de/opus4/frontdoor/index/index/docId/10072
https://hss-opus.ub.ruhr-uni-bochum.de/opus4/files/10072/WilleKai31082021.pdf
https://nbn-resolving.org/urn:nbn:de:hbz:294-100723
https://repository.publisso.de/resource/frl:6447793

Thrombocytosis in children and adolescents—classification, diagnostic approach, and clinical management

Autoren: Clemens Stockklausner R Knöfler Christin Maria Duffert et al.

Quelle: Ann Hematol

Schlagwörter: Adult, Male, 0301 basic medicine, Adolescent, Hydroxyurea/therapeutic use [MeSH], Thrombocytosis/therapy [MeSH], Thrombocythemia, Essential/classification [MeSH], Thrombocytosis/classification [MeSH], Thrombophilia/etiology [MeSH], Disease Management [MeSH], Platelet disorders, Age of Onset [MeSH], Male [MeSH], Thrombophilia/drug therapy [MeSH], Hereditary thrombocytosis, Myelodysplastic-Myeloproliferative Diseases/complications [MeSH], Child [MeSH], Adolescent [MeSH], Algorithms [MeSH], Female [MeSH], Pediatrics, Interferon-alpha/therapeutic use [MeSH], Janus Kinase 2/genetics [MeSH], Adult [MeSH], Humans [MeSH], Severity of Illness Index [MeSH], Review Article, Myeloproliferative neoplasms, Platelet Count [MeSH], Thrombocytosis/diagnosis [MeSH], Thrombocythemia, Essential/genetics [MeSH], Receptors, Thrombopoietin/genetics [MeSH], Germ-Line Mutation [MeSH], Thrombocytosis, Anticoagulants/therapeutic use [MeSH], Calreticulin/genetics [MeSH], Thrombocytosis/etiology [MeSH], Quinazolines/therapeutic use [MeSH], Severity of Illness Index, 03 medical and health sciences, 0302 clinical medicine, Humans, Hydroxyurea, Age of Onset, Child, Germ-Line Mutation, Platelet Count, Anticoagulants, Disease Management, Interferon-alpha, Janus Kinase 2, Myelodysplastic-Myeloproliferative Diseases, 3. Good health, Quinazolines, Female, Calreticulin, Receptors, Thrombopoietin, Algorithms

Zugangs-URL: https://link.springer.com/content/pdf/10.1007/s00277-021-04485-0.pdf
https://pubmed.ncbi.nlm.nih.gov/33712866
https://link.springer.com/content/pdf/10.1007/s00277-021-04485-0.pdf
https://pubmed.ncbi.nlm.nih.gov/33712866/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8195939
https://www.ncbi.nlm.nih.gov/pubmed/33712866
https://link.springer.com/article/10.1007/s00277-021-04485-0
https://repository.publisso.de/resource/frl:6447829

Cerebral oxygen metabolism in adults with sickle cell disease

Autoren: Lena Václavů John C. Wood Esben Thade Petersen et al.

Quelle: Am J Hematol
Václavů, L, Petr, J, Petersen, E T, Mutsaerts, H J M M, Majoie, C B L, Wood, J C, VanBavel, E, Nederveen, A J & Biemond, B J 2020, 'Cerebral oxygen metabolism in adults with sickle cell disease', American Journal of Hematology, vol. 95, no. 4, pp. 401-412. https://doi.org/10.1002/ajh.25727, https://doi.org/10.1002/ajh.25727
Václavů, L, Petr, J, Petersen, E T, Mutsaerts, H J M M, Majoie, C B L, Wood, J C, VanBavel, E, Nederveen, A J & Biemond, B J 2020, ' Cerebral oxygen metabolism in adults with sickle cell disease ', American Journal of Hematology, vol. 95, pp. 401-412 . https://doi.org/10.1002/ajh.25727

Schlagwörter: Adult, Male, Hydroxyurea/therapeutic use, Vasodilator Agents, Fetal Hemoglobin/analysis, Neuroimaging, Anemia, Sickle Cell, Brain Ischemia, Acetazolamide/pharmacology, Young Adult, 03 medical and health sciences, Oxygen Consumption, 0302 clinical medicine, Sickle Cell/blood, Humans, Hydroxyurea, Vasodilator Agents/pharmacology, Treatment Failure, Hypoxia, Hypoxia, Brain, Research Articles, Fetal Hemoglobin, Cerebrovascular Circulation/drug effects, Brain, Anemia, Middle Aged, Brain/diagnostic imaging, Brain Ischemia/etiology, Oxygen/metabolism, Magnetic Resonance Imaging, 3. Good health, Acetazolamide, Oxygen, Cross-Sectional Studies, Cerebrovascular Circulation, Female

Dateibeschreibung: application/pdf

Zugangs-URL: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ajh.25727
https://pubmed.ncbi.nlm.nih.gov/31919876
https://www.narcis.nl/publication/RecordID/oai%3Apure.atira.dk%3Apublications%2F4caac4ea-4d21-4107-96f8-21bbf69ea481
https://research.vumc.nl/en/publications/cerebral-oxygen-metabolism-in-adults-with-sickle-cell-disease-3
https://onlinelibrary.wiley.com/doi/full/10.1002/ajh.25727
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7155077
https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.25727
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7155077
https://research.vumc.nl/en/publications/4caac4ea-4d21-4107-96f8-21bbf69ea481
https://hdl.handle.net/1887/3181525
https://orbit.dtu.dk/en/publications/1b544a0f-1e1a-4829-9c4a-c00484856b0d

Análisis de metilación en pacientes con leucemia mieloide crónica en diferentes instituciones médicas de Medellín

Autoren: Patiño Zapata, Claudia Yaneth Jaramillo Pérez, Luz Marina Medina Gómez, Laura María et al.

Quelle: Repositorio UdeA
Universidad de Antioquia
instacron:Universidad de Antioquia

Schlagwörter: Leukemia, Estudios Transversales, Hidroxiurea - uso terapéutico, Methylation, 3. Good health, Cross-Sectional Studies, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Metilación, Leucemia Mielógena Crónica BCR-ABL Positiva, BCR-ABL Positive, Philadelphia Chromosome, Hydroxyurea - therapeutic use, Chronic, Myelogenous, Cromosoma Filadelfia

Dateibeschreibung: application/pdf

Zugangs-URL: http://revistaamc.sld.cu/index.php/amc/article/view/4981/2712
http://hdl.handle.net/10495/27763

Second malignancies in hydroxyurea and interferon‐treated Philadelphia‐negative myeloproliferative neoplasms

Autoren: Hansen, Iben Onsberg Sørensen, Anders Lindholm Hasselbalch, Hans Carl

Quelle: European Journal of Haematology. 98:75-84

Schlagwörter: Adult, Aged, 80 and over, Male, Myeloproliferative Disorders, Hydroxyurea/therapeutic use, Interferon-alpha/therapeutic use, Interferon-alpha, Neoplasms, Second Primary, Comorbidity, Middle Aged, 3. Good health, Myeloproliferative Disorders/diagnosis, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Neoplasms, 80 and over, Odds Ratio, Humans, Hydroxyurea, Female, Second Primary/diagnosis, Age of Onset, Aged, Retrospective Studies

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/27471124
https://onlinelibrary.wiley.com/doi/10.1111/ejh.12787
https://pubmed.ncbi.nlm.nih.gov/27471124/
https://onlinelibrary.wiley.com/doi/10.1111/ejh.12787/full
https://europepmc.org/article/MED/27471124

Myeloid/Lymphoid neoplasms with abnormalities of PDGFRA

Autoren: Lancaster-Shorts, Katrina L. Chaffin, Joanna Savage, Natasha M et al.

Weitere Verfasser: Lancaster-Shorts, Katrina L. Chaffin, Joanna Savage, Natasha M et al.

Schlagwörter: Myeloid and lymphoid neoplasms with abnormalities of PDGFRA, PDGFRA, CHIC2, eosinophilia, chronic eosinophilic leukemia, tyrosine kinase inhibitor, Leukaemia Section, Adrenal Cortex Hormones/therapeutic use, Antibodies, Monoclonal/therapeutic use, Antineoplastic Agents/*therapeutic use, Disease Management, Eosinophilia/classification/*diagnosis/pathology/*therapy, Eosinophils/drug effects/metabolism/pathology, Hematopoietic Stem Cell Transplantation, Humans, Hydroxyurea/therapeutic use, Interferon-alpha/therapeutic use, Mutation, Receptor, Fibroblast Growth Factor, Type 1/genetics, Platelet-Derived Growth Factor alpha/genetics

Relation: Atlas of Genetics and Cytogenetics in Oncology and Haematology; http://AtlasGeneticsOncology.org/Anomalies/MyeloLymphoPDGFRAID1744.html; Katrina L., Lancaster-Shorts; Joanna, Chaffin; Natasha M, Savage. Myeloid/Lymphoid neoplasms with abnormalities of PDGFRA. Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2018, 4, p. 162-166; http://hdl.handle.net/2042/68889; https://doi.org/10.4267/2042/68889

Verfügbarkeit: http://hdl.handle.net/2042/68889
https://doi.org/10.4267/2042/68889

Hydroxyurea and a cGMP-amplifying agent have immediate benefits on acute vaso-occlusive events in sickle cell disease mice

Autoren: Camila B. Almeida Christoph Scheiermann Nicola Conran et al.

Quelle: Blood, Vol. 120, No 14 (2012) pp. 2879-2888

Schlagwörter: Male, 0301 basic medicine, Erythrocytes, Hydroxyurea/therapeutic use, Pyrazoles/pharmacology, Leukocytes/cytology/drug effects, 3',5'-Cyclic-AMP Phosphodiesterases/antagonists & inhibitors/metabolism, Anemia, Sickle Cell, Cell Communication, Erythrocytes/cytology/drug effects, Mice, 03 medical and health sciences, Vascular Diseases/chemically induced/drug therapy/metabolism, Anemia, Sickle Cell/chemically induced/drug therapy/metabolism, Antisickling Agents, Cell Adhesion, Leukocytes, Antisickling Agents/therapeutic use, Animals, Humans, Hydroxyurea, Cell Adhesion/drug effects, Leukocyte Rolling, Pyrimidines/pharmacology, Cyclic GMP, 0303 health sciences, Tumor Necrosis Factor-alpha/toxicity, 3. Good health, Mice, Inbred C57BL, Cyclic GMP/metabolism, Disease Models, Animal, 3',5'-Cyclic-AMP Phosphodiesterases, Endothelium, Vascular/cytology/drug effects/metabolism, Acute Disease, Pyrazoles, Female, Endothelium, Vascular

Dateibeschreibung: application/pdf

Zugangs-URL: https://ashpublications.org/blood/article-pdf/120/14/2879/1357145/zh804012002879.pdf
https://pubmed.ncbi.nlm.nih.gov/22833547
https://www.sciencedirect.com/science/article/pii/S000649712046344X
https://bv.fapesp.br/pt/publicacao/62110/hydroxyurea-and-a-cgmp-amplifying-agent-have-immediate-benef/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3466969/
http://europepmc.org/articles/PMC3466969
https://ashpublications.org/blood/article/120/14/2879/30514/Hydroxyurea-and-a-cGMP-amplifying-agent-have
https://www.bloodjournal.org/content/bloodjournal/120/14/2879.full.pdf
https://archive-ouverte.unige.ch/unige:113715
https://archive-ouverte.unige.ch/unige:113715
https://doi.org/10.1182/blood-2012-02-409524

Analysis of oxidative status and biochemical parameters in adult patients with sickle cell anemia treated with hydroxyurea, Ceará, Brazil

Autoren: Neto, Paulo Florentino Teixeira Gonçalves, Romélia Pinheiro Elias, Darcielle Bruna Dias et al.

Quelle: Rev Bras Hematol Hemoter
Revista Brasileira de Hematologia e Hemoterapia, Vol 33, Iss 3, Pp 207-210 (2011)
Revista Brasileira de Hematologia e Hemoterapia v.33 n.3 2011
Revista brasileira de hematologia e hemoterapia
Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular (ABHHTC)
instacron:ABHHTC
Revista Brasileira de Hematologia e Hemoterapia, Volume: 33, Issue: 3, Pages: 207-210, Published: JUN 2011

Schlagwörter: 03 medical and health sciences, 0302 clinical medicine, Hydroxyurea/therapeutic use, Iron overload, Hydroxyurea, Diseases of the blood and blood-forming organs, Original Article, RC633-647.5, Reactive oxygen species, Glutathione, Anemia, sickle cell, 3. Good health

Dateibeschreibung: text/html

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/23049297
https://doaj.org/article/99ffe334af9349bb8337c321d4665ab5
https://pubmed.ncbi.nlm.nih.gov/23049297/
http://www.scielo.br/pdf/rbhh/v33n3/v33n3a13.pdf
https://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842011000300013&lng=pt&tlng=pt
https://www.scielo.br/j/rbhh/a/FwKqJxNJnsSYDbrFB4x9kJh/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415728/
http://europepmc.org/articles/PMC3415728
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842011000300013
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842011000300013&lng=en&tlng=en

Evaluation of the concentration of malondialdehyde and nitrite in patients with sickle cell anemia treated or not with hydroxyurea

Autoren: Elias, Darcielle Bruna Dias Freitas, Rivelilson Mendes de Gonçalves, Romélia Pinheiro et al.

Quelle: Einstein (São Paulo), Vol 8, Iss 4, Pp 414-418 (2010)
einstein (São Paulo) v.8 n.4 2010
Einstein (São Paulo)
Instituto Israelita de Ensino e Pesquisa Albert Einstein (IIEPAE)
instacron:IIEPAE
Einstein (São Paulo), Volume: 8, Issue: 4, Pages: 414-418, Published: DEC 2010

Schlagwörter: 0301 basic medicine, 0303 health sciences, Anemia falciforme/quimioterapia, Hidroxiureia/uso terapêutico, Hydroxyurea/therapeutic use, Nitrite, Anemia, 03 medical and health sciences, Malonaldeído, Oxidative stress, Estresse oxidativo, Malondialdehyde, Anemia, sickle cell/drug therapy, Medicine, Thiobarbituric acid reactive substances, sickle cell/drug therapy, Substâncias reativas com ácido tiobarbitúrico, Nitrito

Dateibeschreibung: text/html

Zugangs-URL: http://www.scielo.br/pdf/eins/v8n4/1679-4508-eins-8-4-0414.pdf
https://pubmed.ncbi.nlm.nih.gov/26760321
https://doaj.org/article/e3c1feea725d4a7ea947e0b3a91042d6
https://doaj.org/article/927c64b6e0ef4d1a90e7badb023384c5
https://pubmed.ncbi.nlm.nih.gov/26760321/
https://www.scielo.br/j/eins/a/SLN5J3sYnrqYmSfcNfC6Xgc/
https://www.ncbi.nlm.nih.gov/pubmed/26760321
https://journal.einstein.br/pt-br/article/avaliacao-das-concentracoes-de-malonaldeido-e-nitrito-em-pacientes-com-anemia-falciforme-em-tratamento-ou-nao-com-hidroxiureia/
http://www.scielo.br/j/eins/a/SLN5J3sYnrqYmSfcNfC6Xgc/
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1679-45082010000400414&lng=en&tlng=pt
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1679-45082010000400414
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1679-45082010000400414&lng=en&tlng=en

Patients with sickle cell disease taking hydroxyurea in the Hemocentro Regional de Montes Claros

Autoren: Santos, Fernanda Kelle de Souza Maia, Caroline Nogueira

Quelle: Rev Bras Hematol Hemoter
Revista Brasileira de Hematologia e Hemoterapia, Vol 33, Iss 2, Pp 105-109 (2011)
Revista Brasileira de Hematologia e Hemoterapia v.33 n.2 2011
Revista brasileira de hematologia e hemoterapia
Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular (ABHHTC)
instacron:ABHHTC
Revista Brasileira de Hematologia e Hemoterapia, Volume: 33, Issue: 2, Pages: 105-109, Published: 2011

Schlagwörter: 0301 basic medicine, 03 medical and health sciences, 0302 clinical medicine, Hydroxyurea/therapeutic use, Hydroxyurea, Diseases of the blood and blood-forming organs, Original Article, RC633-647.5, Fetal hemoglobin, Anemia, sickle cell, 3. Good health

Dateibeschreibung: text/html

Zugangs-URL: https://europepmc.org/articles/pmc3520633?pdf=render
https://pubmed.ncbi.nlm.nih.gov/23284256
https://doaj.org/article/5ef21672c8e44b97adc0fa9bfd9cb5b3
https://www.scielo.br/j/rbhh/a/s5Sn5XGxBdchYQZz6s5VKJP/
https://europepmc.org/articles/PMC3520633
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3520633/figure/F1/
http://www.scielo.br/pdf/rbhh/v33n2/v33n2a07.pdf
http://www.scielo.br/j/rbhh/a/s5Sn5XGxBdchYQZz6s5VKJP/
https://www.scielo.br/scielo.php?script=sci_abstract&pid=S1516-84842011000200007&lng=es
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842011000200007
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842011000200007&lng=en&tlng=en

Management of refractory essential thrombocythemia with anagrelide in a patient undergoing hemodialysis

Autoren: Mesquita, Maria Sol, Eugénie Bakoto Malarme, Marianne et al.

Quelle: Clinical Therapeutics. 31:2559-2564

Schlagwörter: Drug Resistance, gastrointestinal bleeding, Kidney Function Tests, hydroxyurea, Kidney Failure, 03 medical and health sciences, Hydroxyurea -- therapeutic use, Fatal Outcome, 0302 clinical medicine, Essential -- drug therapy, Renal Dialysis, Platelet Aggregation Inhibitors -- therapeutic use, Humans, Hydroxyurea, Thrombocythemia, Blood Transfusion, Erythropoietin, Jehovah's Witnesses, Aged, hemodialysis, essential thrombocythemia, Aspirin, Platelet Count, Erythropoietin -- therapeutic use, Sciences bio-médicales et agricoles, Recombinant Proteins, Blood Cell Count, 3. Good health, Chronic -- complications -- drug therapy, Quinazolines, anagrelide, Kidney Failure, Chronic, Female, Aspirin -- therapeutic use, Quinazolines -- therapeutic use, Blood Chemical Analysis, Platelet Aggregation Inhibitors, Thrombocythemia, Essential

Dateibeschreibung: 1 full-text file(s): application/pdf

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/20110000
https://core.ac.uk/display/8909426
https://europepmc.org/article/MED/20110000
https://difusion.ulb.ac.be/vufind/Record/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/107639/Details
https://pubmed.ncbi.nlm.nih.gov/20110000/
https://www.ncbi.nlm.nih.gov/pubmed/20110000
https://www.sciencedirect.com/science/article/pii/S0149291809003968

Análisis de metilación en pacientes con leucemia mieloide crónica en diferentes instituciones médicas de Medellín ; Methylation analysis in patients with chronic myeloid leukemia in different medical institutions in Medellín

Autoren: Patiño Zapata, Claudia Yaneth Jaramillo Pérez, Luz Marina Medina Gómez, Laura María et al.

Weitere Verfasser: Patiño Zapata, Claudia Yaneth Jaramillo Pérez, Luz Marina Medina Gómez, Laura María et al.

Schlagwörter: Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leucemia Mielógena Crónica BCR-ABL Positiva, Methylation, Metilación, Philadelphia Chromosome, Cromosoma Filadelfia, Cross-Sectional Studies, Estudios Transversales, Hidroxiurea - uso terapéutico, Hydroxyurea - therapeutic use

Dateibeschreibung: application/pdf

Relation: Arch. Méd. Camaguey.; 236; 222; 21; Revista Archivo Médico de Camagüey; http://hdl.handle.net/10495/27763; http://revistaamc.sld.cu/index.php/amc/article/view/4981/2712

Verfügbarkeit: http://hdl.handle.net/10495/27763
http://revistaamc.sld.cu/index.php/amc/article/view/4981/2712

The Genomics of New Drugs in Sickle Cell Disease

Autoren: Makis, A. C. Hatzimichael, E. C. Stebbing, J.

Quelle: Pharmacogenomics. 7:909-917

Schlagwörter: 0301 basic medicine, Hydroxyurea/therapeutic use, Sulfasalazine/therapeutic use, Drug Resistance, Anemia, Sickle Cell/*drug therapy/*genetics/metabolism, Anemia, Sickle Cell, Poloxamer, Decitabine, Nitric Oxide, Toxicogenetics, Azacitidine/analogs & derivatives/therapeutic use, 03 medical and health sciences, Antisickling Agents, Antisickling Agents/therapeutic use, Humans, Hydroxyurea, 0303 health sciences, Polymorphism, Genetic, Nitric Oxide/therapeutic use, Poloxamer/therapeutic use, 3. Good health, Sulfasalazine, Butyrates, Phenotype, Butyrates/therapeutic use, Pharmacogenetics, Azacitidine

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/16981849
http://www.ncbi.nlm.nih.gov/pubmed/16981849
https://doi.org/10.2217/14622416.7.6.909
http://olympias.lib.uoi.gr/jspui/handle/123456789/24468

der(8)t(1;8) in myeloblastic transformation of ET with hydroxyurea as the sole prior treatment

Autoren: Chim, CS Ma, SK

Quelle: Hematological Oncology. 23:57-60

Schlagwörter: Male, Translocation, Cell Transformation, Chromosomes, Translocation, Genetic, 03 medical and health sciences, 0302 clinical medicine, Genetic, Myeloid - etiology - genetics, Humans, Hydroxyurea, Chromosome Aberrations, Thrombocytosis, Neoplastic, Leukemia, Middle Aged, 3. Good health, Cell Transformation, Neoplastic, Chromosomes, Human, Pair 1, Leukemia, Myeloid, Karyotyping, Pair 1, Pair 8, Leukemia, Myeloid - etiology - genetics, Thrombocytosis - drug therapy - pathology, Hydroxyurea - therapeutic use, Human, Chromosomes, Human, Pair 8

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/16216034
https://www.ncbi.nlm.nih.gov/pubmed/16216034
https://core.ac.uk/display/37908198
http://onlinelibrary.wiley.com/doi/10.1002/hon.750/abstract
http://hdl.handle.net/10722/76990

Eosinophilic Leukemic Transformation in Polycythemia Rubra Vera (PRV)

Autoren: Chim, CS Ma, SK

Quelle: Leukemia & Lymphoma. 46:447-450

Schlagwörter: Chromosome Aberrations, Male, Hydroxyurea - Therapeutic Use, Hypereosinophilic Syndrome - Complications - Drug Therapy - Pathology, 3. Good health, 03 medical and health sciences, 0302 clinical medicine, Cytogenetic Analysis, Hypereosinophilic Syndrome, Polycythemia Vera - Complications - Drug Therapy, Humans, Hydroxyurea, Polycythemia Vera, Aged

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/15621837
https://www.ncbi.nlm.nih.gov/pubmed/15621837
https://core.ac.uk/display/37983438
https://europepmc.org/article/MED/15621837
https://www.tandfonline.com/doi/abs/10.1080/10428190400007649
http://hub.hku.hk/handle/10722/162788
http://hdl.handle.net/10722/162788